Company: HROW
Filing Date: 2025-09-26
Form Type: 8-K
Source: 0001493152-25-015054
Chunk: 0

Company: HARROW, INC.
Filing Date: 2025-09-26
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry Into a Material Definitive Agreement.

On
September 8, 2025, Harrow, Inc., a Delaware corporation (the “ Company IOI Melt Merger Agreement

Given
the ownership interests in Melt and other relationships of the Company’s management with Melt, the Merger Agreement and the transactions
contemplated thereby were negotiated and approved by a special committee of the Company’s Board of Directors comprised of independent
directors (the “ Independent Committee

Under
the terms of the Merger Agreement and related milestone payment agreement, the Company agreed to acquire the remaining equity interests
of Melt in exchange for an initial cash payment of approximately $4.3 million at closing, and contingent consideration consisting of
cash and Company equity upon achievement of (i) U. S. Food and Drug Administration (“ FDA

  Upon                                                                                            
  Upon                                                                                            
  Upon                                                                                            

The
regulatory and commercial milestones must be achieved, if at all, on or before December 31, 2035.

The
Merger Agreement includes representations and warranties and covenants of the parties customary for a transaction of this nature. Until
the earlier of the termination of the Merger Agreement and the effective time of the acquisition, Melt has agreed to operate its business
in the ordinary course and has agreed to certain other operating covenants. In addition, Melt has agreed to use reasonable best efforts
to obtain approval of the Merger Agreement and the transactions contemplated thereby by the requisite Melt stockholders needed for approval.

The
closing of the Melt acquisition is subject to certain customary closing conditions, including the approval of the requisite stockholders
of Melt, the continued accuracy of representations and warranties and performance of covenants, and the absence of any material adverse
effect.

The
foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full
text of the Merger Agreement and related milestone payment agreement, which the Company expects to file as an exhibit to its Quarterly
Report on Form 10-Q for the three months ending September 30, 2025.

Item
3.02 Unregistered Sales of Equity Securities.